New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 11, 2017 – The FDA approved Ferrer Internacional’s Xepi (ozenoxacin), for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
Download PDF
Return to publications
